Molecular neuroscienceModification of purinergic signaling in the hippocampus of streptozotocin-induced diabetic rats
Section snippets
Reagents
The antibodies against P2X1 (generated against residues 382–399 of rat P2X1 and used at a 1:500 dilution from a 0.6 mg/ml stock), P2X3 (generated against residues 383–397 of rat P2X3 and used at a 1:1000 dilution from a 0.2 mg/ml stock), P2X4 (generated against residues 370–388 of rat P2X4 and used at a 1:500 dilution from a 0.3 mg/ml stock), P2X7 (generated against residues 576–595 of rat P2X7 and used at a 1:5000 dilution from a 0.3 mg/ml stock), P2Y2 (generated against residues 227–244 of
Modification of extracellular ATP concentration and metabolism
We first evaluated if the diabetic rats presented abnormal extracellular ATP levels in the brain. As shown in Fig. 1A, 1 month after STZ-induction of diabetes, the concentration of ATP in the CSF was less than half of that in control rats. The synaptic levels of ATP were also decreased in diabetic rats, as gauged by the reduction of the K+-induced evoked release of ATP from hippocampal nerve terminals (Fig. 1B, C).
We next investigated the rate of extracellular catabolism of ATP by following the
Discussion
The main conclusion of this study is that there is a deregulation of P2 receptor-mediated signaling in the hippocampus of STZ-induced type 1 diabetic rats. We found that there was a decrease in the CSF levels of ATP in diabetic rats, together with a decrease of the evoked release of ATP in hippocampal nerve terminals, suggesting that P2Rs may be facing lower concentration of extracellular ATP. Also the extracellular metabolism of ATP is reduced in nerve terminals from the diabetic hippocampus,
Conclusion
In conclusion, the present study provides evidence showing that the ATP signaling system is compromised in the hippocampus of STZ-treated rats, an experimental model of type 1 diabetes mellitus. These modifications could lead to alterations in the modulation of neurotransmission and gliotransmission, which may contribute to the diabetes-induced progressive cognitive impairment, although the direct impact of such alterations on both neuronal and glial functions remains to be determined. In
Acknowledgments
This work was supported by Fundação para a Ciência e a Tecnologia (FCT, grant POCTI/SAU-NEU/56098/2004) and by Fundo Fundação Oriente/Johnson & Johnson Para a Saúde. João M. N. Duarte acknowledges a PhD grant from FCT (SFRH/BD/17795/2004). Jean Pierre Oses acknowledges a PhD grant from CNPq/Brasil (200127/2005-5).
References (53)
- et al.
Adenosine triphosphate accelerates recovery from hypoxic/hypoglycemic perturbation of guinea pig hippocampal neurotransmission via a P2 receptor
Brain Res
(2002) - et al.
Purinergic P2 receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices
Neuroscience
(2003) - et al.
Glucose deprivation and chemical hypoxia: neuroprotection by P2 receptor antagonists
Neurochem Int
(2001) - et al.
Hypoglycaemia-induced cell death: features of neuroprotection by the P2 receptor antagonist basilen blue
Neurochem Int
(2001) - et al.
P2X and P2Y purinoceptor expression in pancreas from streptozotocin-diabetic rats
Mol Cell Endocrinol
(2003) - et al.
ATP as a presynaptic modulator
Life Sci
(2000) Dr. Jekyll/Mr. Hyde: the dual role of extracellular ATP
J Auton Nerv Syst
(2000)- et al.
Modification of adenosine A1 and A2A receptor density in the hippocampus of streptozotocin-induced diabetic rats
Neurochem Int
(2006) - et al.
Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats
Exp Neurol
(2007) - et al.
Purinergic inhibition of glucose transport in cardiomyocytes
J Biol Chem
(1999)